The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up

• NACT use among SGO members for ovarian cancer is explored given recent trials. • Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively. • Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer. • Very high optimal cytoreduction rates are rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Huelsmann, Erica, Zighelboim, Israel, Ahmed, Amina, Dewdney, Summer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344220/
https://www.ncbi.nlm.nih.gov/pubmed/28317007
http://dx.doi.org/10.1016/j.gore.2017.02.005
Descripción
Sumario:• NACT use among SGO members for ovarian cancer is explored given recent trials. • Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively. • Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer. • Very high optimal cytoreduction rates are reported from SGO members. • Despite recent studies, SGO members don't regularly treat patients with NACT/ID.

Ejemplares similares